Diabetes Consultation Mexico

DIABETES TREATMENT WITH [Treatment name removed] FROM BONE MARROW (AUTOLOGOUS). The field of regenerative medicine is rapidly evolving, opening the way for new therapeutic interventions through cell therapy and tissue engineering approaches that are reshaping the biomedical field. The remarkable plasticity of different subsets of cells derived from human embryonic and adult tissues from different sources (including bone marrow, umbilical cord blood, amniotic fluid, placenta, and adipose tissue) led research efforts to evaluate the use of these cells for numerous diseases, including diabetes and its complications.   Bone marrow is an easily accessible source of multipotent [Treatment name removed], which comprehend hematopoietic [Treatment name removed] progenitors, endothelial, and mesenchymal. These are characterized by the expression of specific surface markers and their ability to differentiate into fat, bone, or cartilage, when exposed to appropriate culture conditions. Recent clinical trials have shown potent immunomodulatory effects of Mesenchymal [Treatment name removed] (MSCs) to treat graft versus host disease, to improve the results of renal allograft using lower immunosuppressive regimens to reduce  immune cell activation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Autologous mesenchymal [Treatment name removed] are shown to improve the lesions of Crohn's disease refractory to other therapies and tested for the treatment of ischemic hearts.

His is a simple and safe three day procedure, which takes growth factor into great consideration. The day before starting treatment blood tests are run as well as blood count, SMAC or Full Blood chemistry, glycosylated hemoglobin and urinalysis, and growth factor applies.The day after the procedure is done under light sedation, more growth factor, a  cell count and cell viability test is done. The procedure takes around 2 hours. Evaluation of: glycosylated hemoglobin, proteinuria, number of medications, neuropathy and changes in visual acuity.Checkup is scheduled 3 months after, at which time the patient will have to repeat the tests. Results are sent via email to assess the effectiveness of therapy, should there be improvement a second procedure can be done after 4 months (to increase the percentage of improvement).Being a systemic disease, application is intravenous.  Since this therapy is not selective, we are able to take advantage of all the different types of [Treatment name removed] contained in bone marrow, and the patient has the opportunity to enhance or regenerate other tissues or organs.